Prostate News and Research

RSS

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary Millennium: The Takeda Oncology Company today announced the initiation of the Phase II portion of a Phase I/II clinical trial of TAK-700 in patients with advanced prostate cancer.

11 Sep 2009

Fau and MELK genes may help improve breast cancer diagnosis and treatment

Researchers at Keele University have identified two genes which may help improve the diagnosis and treatment of breast cancer patients.

11 Sep 2009

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Drug discovery and development company Esperance Pharmaceuticals today announced that it has begun enrollment and dosing of patients in a Phase 1 study of EP-100 in patients with advanced solid tumors. EP-100, the lead candidate from Esperance's Cationic Lytic Peptide (CLYP(TM)) platform technology, is a targeted membrane-disrupting peptide (tMDP) designed to seek and destroy cancer cells that over-express luteinizing hormone releasing hormone (LHRH) receptors on their surfaces.

10 Sep 2009

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.

10 Sep 2009

Lack of awareness in aged men reagarding prostate cancer treatment options

Prostate cancer remains one of the most commonly diagnosed cancers in the United States. In fact, one in six men will develop prostate cancer. It is also the second-leading cause of cancer death in the United States. But a recent survey suggests that many men at risk for the cancer still aren't aware of all available treatment options.

10 Sep 2009

New type of stem cell in the prostate may be a source for prostate cancer, say researchers

A new type of stem cell discovered in the prostate of adult mice can be a source of prostate cancer, according to a new study by researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian Hospital.

10 Sep 2009

GENova Biotherapeutics discusses its anti-cancer drug development strategy

GENova Biotherapeutics, Inc., ("GENova"), today released important information about its anti-cancer drug development strategy and its unique niche in the drug development industry.

9 Sep 2009

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

The TURis plasma vaporization electrode does not cut off tissue with a loop, but energetically vaporizes the tissue with a small button electrode. With the help of the latest plasma technology, cells can be removed by merely gliding the electrode over the prostate tissue.

From Evident Corporation - Life Sciences 9 Sep 2009

Prostate cancer treatment options discussed in a study

A new study in the Journal of the American Medical Association (JAMA) appears to support the theory outlined in earlier studies that men with more advanced forms of prostate cancer don't benefit from a combination of hormone and radiation therapy.

9 Sep 2009

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

9 Sep 2009

Research study highlights unique aspects of tumor immunology

Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.

9 Sep 2009

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced that it has completed patient enrollment in its multi-centre, double-blinded, placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in males with moderate to severe benign prostatic hyperplasia (BPH), a common and bothersome urological condition that affects more than 50 million men worldwide.

8 Sep 2009

Active cannabis chemicals halt prostate cancer cell growth

ACTIVE chemicals in cannabis have been shown to halt prostate cancer cell growth according to research published in the British Journal of Cancer today.

8 Sep 2009

Presence of virus linked with malignant human prostate cancer cells

In a finding with potentially major implications for identifying a viral cause of prostate cancer, researchers at the University of Utah and Columbia University medical schools have reported that a type of virus known to cause leukemia and sarcomas in animals has been found for the first time in malignant human prostate cancer cells.

7 Sep 2009

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Nanoparticle delivery of diphtheria toxin-encoding DNA that expresses selectively in ovarian cancer cells reduced the burden of ovarian tumors in mice, and researchers expect that this therapy could be tested in humans with advanced ovarian cancer within 18 to 24 months, according to a report in Cancer Research. If additional tests are successful, these finding could lead to a new treatment for ovarian cancer, which now causes more than 15,000 deaths each year in the United States. Because it is usually diagnosed at a relatively late stage, ovarian cancer is one of the most deadly forms of the disease.

7 Sep 2009

Two new da Vinci Si HD Surgical System robots added to Swedish Medical Center

As one of the first medical centers in the Northwest to perform robot-assisted surgery, Swedish Medical Center is home to the fastest-growing and most experienced robot-assisted surgical program in the region. Swedish established the multidisciplinary robot-assisted surgical program in 2005 and has since performed more than 2,000 robot-assisted surgeries, more than any other program in the region.

4 Sep 2009

Periurethral suspension technique results in greater continence rates after RALIP

The September issue of European Urology, the official journal of the European Association of Urology, features an article and a video in the Surgery in Motion section by Vipul R. Patel et al, showing that the periurethral suspension technique results in significantly greater continence rates at 3 months after robot-assisted laparoscopic radical prostatectomy (RALP).

4 Sep 2009

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

A key compound resupplies bone marrow with fast-acting stem cells that can more quickly rekindle blood cell production, according to a study published online today in the journal Blood. While the study was in mice, in the study authors say it has the potential to increase survival among patients with life-threatening blood cell shortages.

3 Sep 2009

Algeta partners with Bayer for development and commercialization of Alpharadin drug

Algeta Retains Option for Co-promotion and Profit Sharing in USA - Potential deal value of $800 million (EUR560m*) plus tiered double digit royalties - Algeta to receive $61 million (EUR42.5m) cash upfront, followed by development and sales milestones - Algeta retains option for co-promotion and profit-sharing in USA - Algeta and Bayer will jointly develop Alpharadin, with Bayer contributing a substantial majority of the costs of future development

3 Sep 2009

IGRT offers improved treatment results for obese prostate cancer patients

Moderately to severely obese prostate cancer patients may have improved treatment outcomes when treated with image-guided radiation therapy (IGRT) over traditional external beam radiation therapy (EBRT) because IGRT corrects for prostate shifts, which, if not planned for, can lead to incorrect doses of radiation to the disease site, according to a study in the September 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

3 Sep 2009

Prostate News and Research

Phase II clinical trial of TAK-700 for treating advanced prostate cancer commences

Fau and MELK genes may help improve breast cancer diagnosis and treatment

Esperance Pharmaceuticals begins human clinical trials of its EP-100 cancer therapeutic candidate

Protox' Phase 2 study of PRX302 for treating BPH provides positive results

Lack of awareness in aged men reagarding prostate cancer treatment options

New type of stem cell in the prostate may be a source for prostate cancer, say researchers

GENova Biotherapeutics discusses its anti-cancer drug development strategy

TURis plasma vaporization electrode for benign prostatic hyperplasia therapy

Prostate cancer treatment options discussed in a study

GENova Biotherapeutics files patent for Prostaganin anti-cancer drug

Research study highlights unique aspects of tumor immunology

Patient enrollment for Phase 2b study of PRX302 completed by Protox Therapeutics

Active cannabis chemicals halt prostate cancer cell growth

Presence of virus linked with malignant human prostate cancer cells

Nanoparticle-delivered suicide gene therapy effectively reduces ovarian tumor burden in mice

Two new da Vinci Si HD Surgical System robots added to Swedish Medical Center

Periurethral suspension technique results in greater continence rates after RALIP

Study identifies key compound that quickens recovery from life-threatening blood cell shortages

Algeta partners with Bayer for development and commercialization of Alpharadin drug

IGRT offers improved treatment results for obese prostate cancer patients

What to know about prostate cancer eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News